{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:27:14Z","timestamp":1774358834470,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,12,8]],"date-time":"2008-12-08T00:00:00Z","timestamp":1228694400000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p><jats:bold>Abstract\u2002<\/jats:bold> Sinovac Biotech started to develop prototype pandemic influenza H5N1 vaccines in March 2004. On 2 April 2008, Sinovac\u2019s inactivated, aluminium\u2010adjuvanted, whole\u2010virion prototype pandemic influenza A (H5N1) vaccine (PanFlu\u2122) was granted production licensure by the China regulatory authority State Food and Drug Administration. The whole\u2010virion H5N1 vaccine was manufactured in embryonated hens\u2019 eggs using the reassortant strain NIBRG\u201014 (A\/Vietnam\/1194\/2004\u2010A\/PR\/8\/34) as vaccine virus. It showed good safety, immunogenicity and cross\u2010reactivity in immunologically na\u00efve adults. In primed adults, the vaccine induced a strong booster response. Plasma from a vaccinated individual showed a beneficial effect following passive immunotherapy of an H5N1 human infection case. This article reviews the process, status and results of clinical evaluation of Sinovac\u2019s whole\u2010 and split\u2010virion H5N1 vaccines by focusing on the whole\u2010virion vaccine.<\/jats:p>","DOI":"10.1111\/j.1750-2659.2008.00067.x","type":"journal-article","created":{"date-parts":[[2008,12,9]],"date-time":"2008-12-09T22:50:59Z","timestamp":1228863059000},"page":"237-242","source":"Crossref","is-referenced-by-count":7,"title":["Safety and immunogenicity of Sinovac\u2019s prototype pandemic influenza H5N1 vaccines: a review on clinical trials"],"prefix":"10.1111","volume":"2","author":[{"given":"Yuan\u2010Zheng","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei\u2010Dong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,30]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11212-0"},{"key":"e_1_2_7_3_2","volume-title":"H5N1 Avian Influenza: Timeline of Major Events","author":"WHO","year":"2008"},{"key":"e_1_2_7_4_2","volume-title":"Cumulative Number of Confirmed Human Cases of Avian Influenza A\/(H5N1) Reported to WHO","author":"WHO","year":"2008"},{"key":"e_1_2_7_5_2","volume-title":"Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application (CPMP\/VEG\/4717\/03)","author":"European Committee for Proprietary Medicinal Products","year":"2004"},{"key":"e_1_2_7_6_2","volume-title":"Antigenic and Genetic Characteristics of H5N1 Viruses and Candidate H5N1 Vaccine Viruses Developed for Potential Use as Pre\u2010pandemic Vaccines","author":"WHO","year":"2007"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69294-5"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/595832"},{"key":"e_1_2_7_9_2","volume-title":"Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines","author":"US Food and Drug Administration","year":"2007"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/526537"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60493-6"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055778"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68656-X"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61297-5"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05066-2"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/508174"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/428948"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2007.00033.x"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1750-2659.2008.00067.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1750-2659.2008.00067.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1750-2659.2008.00067.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:43:31Z","timestamp":1695501811000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1750-2659.2008.00067.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1750-2659.2008.00067.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1750-2659.2008.00067.x","archive":["Portico"],"relation":{},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}